Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis

Rheumatology

Volumn 46, Issue 1, 2007, Pages 124-130

  Yamasaki, Yoshioki ^a   Yamada, H ^a   Yamasaki, M ^a   Ohkubo, M ^a   Azuma, K ^a   Matsuoka, S ^a   Kurihara, Y ^a   Osada, H ^a   Satoh, M ^b   Ozaki, S ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cyclophosphamide; Dermatomyositis; Interstitial pneumonia; Intravenous pulse; Polymyositis

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; HISTIDINE TRANSFER RNA LIGASE; ISONIAZID; MESNA; METHYLPREDNISOLONE; OXYGEN; PREDNISOLONE;

ADULT; AGED; ARTHRITIS; ARTICLE; AZOOSPERMIA; CLINICAL ARTICLE; DERMATOMYOSITIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG FUNCTION TEST; MALE; MALIGNANT NEOPLASTIC DISEASE; MYCOBACTERIOSIS; MYOSITIS; OPEN STUDY; OPPORTUNISTIC INFECTION; OXYGEN THERAPY; PNEUMOCYSTIS PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; SCORING SYSTEM; TUBERCULOSIS; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; CYCLOPHOSPHAMIDE; DERMATOMYOSITIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; POLYMYOSITIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 33845562221     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel112     Document Type: Article

References (42)

1. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004;63:297-301.
2. Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miyamoto T. Interstitial lung disease in dermatomyositis: Clinicopathological study. J Rheumatol 1987;14:102-7.
3. Hidano A, Torikai S, Uemura T, Shimizu S. Malignancy and interstitial pneumonitis as fatal complications in dermatomyositis. J Dermatol 1992;19:153-60.
4. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003;22:245-50.
5. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988;18:29-37.
6. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996;14:263-74.
7. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: A longitudinal study of 162 cases. Medicine 2004;83:35-42.
8. Fujisawa T, Suda T, Nakamura Y et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005;32:58-64.
9. Nawata Y, Kurasawa K, Takabayashi K et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: Prediction and treatment with cyclosporine. J Rheumatol 1999;26: 1527-33.
10. Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
11. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: Clinical course and response to treatment. Semin Arthritis Rheum 2003;32:273-84.
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
13. Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 1999; 11:475-82.
14. Arakawa H, Kurihara Y, Nakajima Y. Pulmonary fat embolism syndrome: CT findings in six patients. J Comput Assist Tomogr 2000;24:24-9.
15. Arakawa H, Yamada H, Kurihara Y et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: Serial high-resolution CT findings and functional correlation. Chest 2003;123:1096-103.
16. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64.
17. Reeves WH, Satoh M, McCauliffe DP. Autoantibody testing by non-FITC methods. In: Rose, NR, Hamilton RG, Detrick B, eds. Manual of clinical laboratory immunology. Washington, DC: American Society of Microbiology Press, 2001:933-50.
18. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989;44:280-8.
19. O'Donnell K, Keogh B, Cantin A, Crystal RG. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1987;136:288-92.
20. Dayton CS, Schwartz DA, Helmers RA et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest 1993;103:69-3.
21. Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102:1090-4.
22. Kolb M, Kirschner J, Riedel W, Wirtz H, Schmidt M. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur Respir J 1998;12:1409-14.
23. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994;37:1290-6.
24. Douglas WW, Tazelaar HD, Hartman TE et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164:1182-5.
25. Maccioni FJ, Colebatch HJ. Management of fibrosing alveolitis with polymyositis dermatomyositis. Aust N Z J Med 1990;20:806-10.
26. al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol 1989;16:1592-6.
27. Kobayashi I, Yamada M, Takahashi Y et al. Interstitial lung disease associated with juvenile dermatomyositis: Clinical features and efficacy of cyclosporin A. Rheumatology 2003;42:371-4.
28. Miyake S, Ohtani Y, Sawada M et al. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:128-33.
29. Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: Is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 1997;26:24-9.
30. Kameda H, Nagasawa H, Ogawa H et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005;32:1719-26.
31. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439-46.
32. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353:1762-3.
33. Ochi S, Nanki T, Takada K et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005;23:707-10.
34. Mino M, Noma S, Taguchi Y, Tomii K, Kohri Y, Oida K. Pulmonary involvement in polymyositis and dermatomyositis: Sequential evaluation with CT. Am J Roentgenol 1997;169:83-7.
35. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998;41:1215-20.
36. Oddis CV. Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 2000;12:492-7.
37. Mihara N, Johkoh T, Ichikado K et al. Can acute interstitial pneumonia be differentiated from bronchiolitis obliterans organizing pneumonia by high-resolution CT? Radiat Med 2000; 18:299-304.
38. Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 2002;359:775-80.
39. Godeau B, Coutant-Perronne V, Le Thi Huong D et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases. J Rheumatol 1994;21:246-51.
40. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999;42:780-9.
41. Rossi SE, Erasmus JJ, Volpacchio M, Franquet T, Castiglioni T, McAdams HP. "Crazy-paving" pattern at thin-section CT of the lungs: radiologic-pathologic overview. Radiographics 2003;23: 1509-19.
42. Marie I, Hachulla E, Cherin P et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53:155-65.